Epstein-Barr Virus Antibodies to Differentiate Multiple Sclerosis From Other Neuroinflammatory Diseases - PubMed
4 days ago
- #Neuroinflammatory Diseases
- #Multiple Sclerosis
- #Epstein-Barr Virus
- Epstein-Barr virus (EBV)-derived Epstein-Barr nuclear antigen 1 (EBNA-1) peptide antibody titers may help differentiate multiple sclerosis (MS) from myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and neuromyelitis optica spectrum disorder (NMOSD).
- The study involved 2091 patients with neuroinflammatory diseases and 1976 healthy controls, assessing longitudinal plasma EBNA-1 peptide immunoglobulin G (IgG) titers.
- Results showed that 96.2% of MS patients in the test cohort had high-level EBNA-1 titers in multiple follow-ups, compared to only 7.7% of MOGAD and 18.0% of NMOSD patients.
- In the validation cohort, 95.1% of MS patients had persistent high-level EBNA-1 titers, versus 16.7% of MOGAD and 17.6% of NMOSD patients.
- Persistent high-level EBNA-1 peptide antibody titers could serve as a reliable biomarker for distinguishing MS from MOGAD and NMOSD.